Systematic review and meta-analysis: Susceptibility-guided versus empirical antibiotic treatment for Helicobacter pylori infection

Journal of Antimicrobial Chemotherapy

Volumn 70, Issue 9, 2015, Pages 2447-2455

  López Góngora, Sheila ^a   Puig, Ignasi ^b,c,d   Calvet, Xavier ^a,c,e   Villoria, Albert ^a,c,e   Baylina, Mireia ^a   Muñoz, Neus ^a   Sanchez Delgado, Jordi ^a,c,e   Suarez, David ^f   García Hernando, Victor ^a   Gisbert, Javier P ^e,g  

^a Centre de Salut Mental   (Spain)

^b Althaia   (Spain)

^c UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^d UNIVERSITAT INTERNACIONAL DE CATALUNYA   (Spain)

^e INSTITUTO DE SALUD CARLOS III   (Spain)

^f HOSPITAL DE SABADELL   (Spain)

^g Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT;

ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ARTICLE; CLINICAL PRACTICE; COMPARATIVE STUDY; EMPIRICISM; ENDOSCOPY; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; META ANALYSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMATIC REVIEW; TASK PERFORMANCE; DRUG EFFECTS; DRUG THERAPY; HELICOBACTER INFECTIONS; ISOLATION AND PURIFICATION; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; PROCEDURES; TREATMENT OUTCOME;

ANTI-BACTERIAL AGENTS; DRUG THERAPY; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; MICROBIAL SENSITIVITY TESTS; TREATMENT OUTCOME;

EID: 84940456718     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkv155     Document Type: Article

References (56)

1. McColl KE. Clinical practice. Helicobacter pylori infection. N Engl J Med 2010; 362: 1597-604.
2. Malfertheiner P, Megraud F, O'Morain C et al. Current European concepts in the management of Helicobacter pylori infection-the Maastricht Consensus Report. The European Helicobacter pylori Study Group (EHPSG). Eur J Gastroenterol Hepatol 1997; 9: 1-2.
3. Mégraud F, Lehn N, Lind T et al. Antimicrobial susceptibility testing of Helicobacter pylori in a large multicenter trial: the MACH 2 study. Antimicrob Agents Chemother 1999; 43: 2747-52.
4. Malfertheiner P, Megraud F, O'Morain CA et al. Management of Helicobacter pylori infection-the Maastricht IV/Florence Consensus Report. Gut 2012; 61: 646-64.
5. Graham DY, Fischbach L. Helicobacter pylori treatment in the era of increasing antibiotic resistance. Gut 2010; 59: 1143-53.
6. Megraud F, Coenen S, Versporten A et al. Helicobacter pylori resistance to antibiotics in Europe and its relationship to antibiotic consumption. Gut 2013; 62: 34-42.
7. Wenzhen Y, Yumin L, Quanlin G et al. Is antimicrobial susceptibility testing necessary before first-line treatment for Helicobacter pylori infection? Meta-analysis of randomized controlled trials. Intern Med 2010; 49: 1103-9.
8. Liberati A, Altman DG, Tetzlaff J et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidemiol 2009; 62: e1-34.
9. Higgins JPT, Green S. Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. www.cochrane-handbook.org.
10. Review Manager (RevMan) Version 5.2. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2012.
11. Street ME, Caruana P, Caffarelli C et al. Antibiotic resistance and antibiotic sensitivity based treatment in Helicobacter pylori infection: advantages and outcome. Arch Dis Child 2001; 84: 419-22.
12. Lopes AI, Oleastro M, Palha A et al. Antibiotic-resistant Helicobacter pylori strains in Portuguese children. Pediatr Infect Dis J 2005; 24: 404-9.
13. Nguyen TVH, Bengtsson C, Yin L et al. Eradication of Helicobacter pylori in children in Vietnam in relation to antibiotic resistance. Helicobacter 2012; 17: 319-25.
14. Gomollon F, Sicilia B, Ducons JA et al. Third line treatment for Helicobacter pylori: a prospective, culture-guided study in peptic ulcer patients. Aliment Pharmacol Ther 2000; 14: 1335-8.
15. Furuta T, Sugimoto M, Nakamura A et al. Susceptibility to antibiotics and drug metabolism in patients with H. pylori infection refractory to the initial treatment-therapeutic strategy based on susceptibility to CAM and CYP2C19 polymorphism. Nihon Rinsho 2005; 63 Suppl 11: 426-33.
16. Romano M, Iovene MR, Montella F et al. Pretreatment antimicrobialsusceptibility testing in the eradication of H. pylori infection. Am J Gastroenterol 2000; 95: 3317-8.
17. Seppala K, Kosunen TU, Nuutinen H et al. Cure of Helicobacter pylori infection after failed primary treatment: one-center results from 120 patients. Scand J Gastroenterol 2000; 35: 929-34.
18. Graham DY, Osato MS, Hoffman J et al. Furazolidone combination therapies for Helicobacter pylori infection in the United States. Aliment Pharmacol Ther 2000; 14: 211-5.
19. Breuer T, Graham DY. Costs of diagnosis and treatment of Helicobacter pylori infection: when does choosing the treatment regimen based on susceptibility testing become cost effective? Am J Gastroenterol 1999; 94: 725-9.
20. Zullo A, Hassan C, Lorenzetti R et al. A clinical practice viewpoint: to culture or not to culture Helicobacter pylori? Dig Liver Dis 2003; 35: 357-61.
21. Nagahara A, Sato N. Is antimicrobial susceptibility testing necessary before second-line treatment for Helicobacter pylori infection? Nihon Rinsho 2005; 63 Suppl 11: 421-5.
22. Furuta T, Shirai N, Kodaira M et al. Pharmacogenomics-based tailored versus standard therapeutic regimen for eradication of H. pylori. Clin Pharmacol Ther 2007; 81: 521-8.
23. Avidan B, Melzer E, Keller N et al. The effect of culture results for Helicobacter pylori on the choice of treatment following failure of initial eradication. Isr Med Assoc J 2001; 3: 163-5.
24. Biscontri M, Lisi L, Pellegrini M et al. Helicobacter pylori infection: culture and antibiotic essay. Coltura e antibiogramma nell'infezione da Helicobacter pylori. Argomenti di Gastroenterologia Clinica 2001; 14: 81-8.
25. Cammarota G, Martino A, Pirozzi G et al. High efficacy of 1-week doxycycline-and amoxicillin-based quadruple regimen in a cultureguided, third-line treatment approach for Helicobacter pylori infection. Aliment Pharmacol Ther 2004; 19: 789-95.
26. Cosme A, Montes M, Martos M et al. Usefulness of antimicrobial susceptibility in the eradication of Helicobacter pylori. Clin Microbiol Infect 2013; 19: 379-83.
27. Fiorini G, Vakil N, Zullo A et al. Culture-based selection therapy for patients who did not respond to previous treatment for Helicobacter pylori infection. Clin Gastroenterol Hepatol 2013; 11: 507-10.
28. Gasbarrini A, Ojetti V, Armuzzi A et al. Efficacy of a multistep strategy for Helicobacter pylori eradication. Aliment Pharmacol Ther 2000; 14: 79-83.
29. Kawai T, Yamagishi T, Yagi K et al. Tailored eradication therapy based on fecal Helicobacter pylori clarithromycin sensitivities. J Gastroenterol Hepatol 2008; 23: S171-4.
30. Lamouliatte H, Megraud F, Delchier JC et al. Second-line treatment for failure to eradicate Helicobacter pylori: a randomized trial comparing four treatment strategies. Aliment Pharmacol Ther 2003; 18: 791-7.
31. Lee HJ, Kim JI, Cheung DY et al. Eradication of Helicobacter pylori according to 23S ribosomal RNA point mutations associated with clarithromycin resistance. J Infect Dis 2013; 208: 1123-30.
32. Liou JM, Chen CC, Chang CY et al. Efficacy of genotypic resistanceguided sequential therapy in the third-line treatment of refractory Helicobacter pylori infection: a multicentre clinical trial. J Antimicrob Chemother 2013; 68: 450-6.
33. Marzio L, Coraggio D, Capodicasa S et al. Role of the preliminary susceptibility testing for initial and after failed therapy of Helicobacter pylori infection with levofloxacin, amoxicillin, and esomeprazole. Helicobacter 2006; 11: 237-42.
34. Miwa H, Nagahara A, Kurosawa A et al. Is antimicrobial susceptibility testing necessary before second-line treatment for Helicobacter pylori infection? Aliment Pharmacol Ther 2003; 17: 1545-51.
35. Molina-Infante J, Pazos-Pacheco C, Vinagre-Rodriguez G et al. Nonbismuth quadruple (concomitant) therapy: empirical and tailored efficacy versus standard triple therapy for clarithromycin-susceptible Helicobacter pylori and versus sequential therapy for clarithromycinresistant strains. Helicobacter 2012; 17: 269-76.
36. Neri M, Milano A, Laterza F et al. Role of antibiotic sensitivity testing before first-line Helicobacter pylori eradication treatments. Aliment Pharmacol Ther 2003; 18: 821-7.
37. Romano M, Marmo R, Cuomo A et al. Pretreatment antimicrobial susceptibility testing is cost saving in the eradication of Helicobacter pylori. Clin Gastroenterol Hepatol 2003; 1: 273-8.
38. Sugimoto M, Uotani T, Sahara S et al. Efficacy of tailored Helicobacter pylori eradication treatment based on clarithromycin susceptibility and maintenance of acid secretion. Helicobacter 2014; 19: 312-8.
39. Tay CY, Windsor HM, Thirriot F et al. Helicobacter pylori eradication in Western Australia using novel quadruple therapy combinations. Aliment Pharmacol Ther 2012; 36: 1076-83.
40. Toracchio S, Cellini L, Di Campli E et al. Role of antimicrobial susceptibility testing on efficacy of triple therapy in Helicobacter pylori eradication. Aliment Pharmacol Ther 2000; 14: 1639-43.
41. Vicente R, Sicilia B, Gallego S et al. Helicobacter pylori eradication in patients with peptic ulcer after two treatment failures: a prospective culture-guided study. Gastroenterol Hepatol 2002; 25: 438-42.
42. Wang G, Zhao Q, Li S. Study of drug sensitivity test in Helicobacter pylori eradication therapy. J Clin Intern Med 2008; 25: 474-7.
43. Yahav J, Samra Z, Niv Y et al. Susceptibility-guided vs. empiric retreatment of Helicobacter pylori infection after treatment failure. Dig Dis Sci 2006; 51: 2316-21.
44. Zhou JHH, Wu M, Jiang X. Role of drug sensitivity test in the triple therapy for eradication of Helicobacter pylori. Chin J Gastroenterol 2010; 15: 358-60.
45. Park CS, Lee SM, Park CH et al. Pretreatment antimicrobial susceptibilityguided vs. clarithromycin-based triple therapy for Helicobacter pylori eradication in a region with high rates of multiple drug resistance. Am J Gastroenterol 2014; 109: 1595-602.
46. Zhuo RP, Chen XP, Wu SZ et al. Clinical effects of quadruple therapy based on antimicrobial susceptibility testing in treatment of Helicobacter pylori associated upper digestive tract diseases. World Chin J Digestol 2015; 23: 196-201.
47. Martos M, Bujanda L, Salicio Y et al. Clarithromycin for first-line treatment of Helicobacter pylori infection after culture in high-resistance regions. Eur J Gastroenterol Hepatol 2014; 26: 1380-4.
48. Gisbert JP, Gisbert JL, Marcos S et al. Third-line rescue therapy with levofloxacin is more effective than rifabutin rescue regimen after two Helicobacter pylori treatment failures. Aliment Pharmacol Ther 2006; 24: 1469-74.
49. Gisbert JP, Gisbert JL, Marcos S et al. Empirical rescue therapy after Helicobacter pylori treatment failure: a 10-year single-centre study of 500 patients. Aliment Pharmacol Ther 2008; 27: 346-54.
50. Nishizawa T, Suzuki H, Nakagawa I et al. Gatifloxacin-based triple therapy as a third-line regimen for Helicobacter pylori eradication. J Gastroenterol Hepatol 2008; 23 Suppl 2: S167-70.
51. Tursi A, Picchio M, Elisei W. Efficacy and tolerability of a third-line, levofloxacin-based, 10-day sequential therapy in curing resistant Helicobacter pylori infection. J Gastrointestin Liver Dis 2012; 21: 133-8.
52. Gisbert JP, Castro-Fernandez M, Bermejo F et al. Third-line rescue therapy with levofloxacin after two H. pylori treatment failures. Am J Gastroenterol 2006; 101: 243-47.
53. Cheon JH, Kim N, Lee DH et al. Trial of moxifloxacin-containing triple therapy after initial and second-line treatment failures for Helicobacter pylori infection. Korean J Gastroenterol 2005; 45: 111-7.
54. Treiber G, Ammon S, Malfertheiner P et al. Impact of furazolidonebased quadruple therapy for eradication of Helicobacter pylori after previous treatment failures. Helicobacter 2002; 7: 225-31.
55. Hirata Y, Ohmae T, Yanai A et al. Sitafloxacin resistance in Helicobacter pylori isolates and sitafloxacin-based triple therapy as a third-line regimen in Japan. Int J Antimicrob Agents 2012; 39: 352-5.
56. Nishizawa T, Suzuki H, Maekawa T et al. Dual therapy for third-line Helicobacter pylori eradication and urea breath test prediction. World J Gastroenterol 2012; 18: 2735-8.